Development of small molecule OGG1 Inhibitor and proof of concept in bleomycin-induced disease model of Inflammation and pulmonary Fibrosis

Project description

A molecular inhibitor against pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive condition characterised by pathological inflammation and scarring in the lungs. The causes of IPF are unknown, and there is no cure, with most patients surviving approximately three years after diagnosis. Scientists of the EU-funded DOIIF project had previously developed an inhibitor of the OGG1 enzyme, which is implicated in DNA repair during oxidative stress. Since inhibition of OGG1 seems to reduce inflammation and fibrosis and slow down IPF, researchers aim to take a lead compound through preclinical development and clinical phase 1/2a for further commercialisation.

Fields of science

Host institution

KAROLINSKA INSTITUTET

Net EU contribution

€ 150 000,00

Address

Nobels Vag 5
17177 Stockholm
Sweden

Region

Östra Sverige Stockholm Stockholms län

Activity type

Higher or Secondary Education Establishments

Links

Contact the organisation Website

Participation in EU R&I programmes

HORIZON collaboration network

Non-EU contribution

No data

Beneficiaries (1)